CytomX Therapeutics, Inc.
CTMX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CTMX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CTMX
CytomX Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing conditionally activated PROBODY therapeutics, with its lead candidate CX-2051 in Phase 1/2 trials and a cash position of $17.2M as of 2026-06-30 [sec].
Key risk: Unproven platform technology
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 2 clinical trials for CytomX Therapeutics, Inc..
CytomX Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing conditionally activated PROBODY therapeutics, with its lead candidate CX-2051 in Phase 1/2 trials and a cash position of $17.2M as of 2026-06-30 [sec].
- CytomX is a clinical-stage oncology biopharmaceutical company focused on its PROBODY conditionally activated platform technology [sec_mda · as of 2026-05-07].
- Lead candidate CX-2051 is in Phase 1/2 development; dose expansions at 7.2, 8.6, and 10 mg/kg Q3W are underway, with a Phase 2 study in colorectal cancer planned for H1 2026 [sec · filed 2025-05-12].
- As of 2026-06-30, the company reported cash & equivalents of $17.2M, total revenue of $1.4M, and a net loss of $20.7M [sec].
- The company expects existing capital resources to fund operations into Q2 2027 based on current plans [sec_mda · as of 2026-03-16].
- CytomX has raised capital through an ATM offering ($16.3M net in 2025) and an underwritten public offering ($93.4M net in May 2025) [sec_mda · as of 2026-03-16].
What works
- PROBODY platform is designed for conditionally activated therapeutics, potentially improving tumor targeting and reducing systemic toxicity [sec_mda · as of 2026-05-07].
- CX-2051 Phase 1 data showed no Grade 4 or 5 treatment-related adverse events and no interstitial lung disease or febrile neutropenia as of the data cutoff [sec · filed 2025-05-12].
- Company has a clear clinical development path with dose expansion cohorts and a planned Phase 2 study in colorectal cancer [sec · filed 2025-05-12].
What to weigh
- The PROBODY technology is novel and unproven, with clinical-stage product candidates in early development and others in preclinical stages [sec · filed 2025-05-12].
- CytomX has a limited cash runway of $17.2M as of 2026-06-30, with a net loss of $20.7M in the latest quarter, raising going-concern risk [sec].
- The company faces uncertainties in raising sufficient funds to support its planned research and development [sec · filed 2025-05-12].
- CX-2051 is in initial clinical development; there is no guarantee of successful completion or regulatory approval [sec · filed 2025-08-13].
From the filings
Quoted directly from source documents.
CX-2051 Phase 1 data showed no Grade 4/5 TRAEs and no ILD or febrile neutropenia.
“No Grade 4 or 5 TRAEs were observed. No events of interstitial lung disease or febrile neutropenia were reported as of the data cutoff.”
SEC filings · May 12, 2025
Company expects to provide additional Phase 1 data update in Q1 2026 and initiate Phase 2 in colorectal cancer in H1 2026.
“The Company expects to provide an additional Phase 1 data update in the first quarter of 2026. The Company is planning initiation of a Phase 2 study in colorectal cancer in the first half of 2026.”
SEC filings · May 12, 2025
Company expects existing capital to fund operations into Q2 2027.
“Based upon our current operating plan and liquidity requirements, we expect our existing capital resources will be sufficient to fund operations into the second quarter of 2027.”
SEC MD&A · March 16, 2026
Risks & what to watch (4)›
Key risks
- Unproven platform technology — PROBODY technology is novel and unproven; clinical candidates are in early stages [sec · filed 2025-05-12].
- Limited cash runway — Cash of $17.2M as of 2026-06-30 with net loss of $20.7M; runway only into Q2 2027 [sec] [sec_mda · as of 2026-03-16].
- Dependence on CX-2051 success — Lead candidate CX-2051 is in early clinical development; failure could materially impact the company [sec · filed 2025-08-13].
- Financing uncertainty — Company may need additional funding to complete development; uncertainties in raising capital [sec · filed 2025-05-12].
What to watch
- Additional Phase 1 data update for CX-2051 expected in Q1 2026 [sec · filed 2025-05-12].
- Initiation of Phase 2 study in colorectal cancer planned for H1 2026 [sec · filed 2025-05-12].
- Cash burn rate and any future capital raises given $17.2M cash as of 2026-06-30 [sec].
- Regulatory updates or partnership announcements regarding PROBODY platform [sec_mda · as of 2026-05-07].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run CytomX Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CytomX Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
54.4 months
D/E 0.26 · 0% dilution
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
0 buys · 5 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
178
Total value held
$871.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 31,955,637 | $150.2M |
| perceptive advisors llc | 20,197,648 | $94.9M |
| vanguard capital management llc | 17,466,236 | $82.1M |
| bank of america corp /de/ | 10,202,785 | $48.0M |
| citadel advisors llc | 5,899,193 | $27.7M |
| state street corp | 5,663,408 | $26.6M |
| blackrock, inc. | 5,228,280 | $24.6M |
| baker bros. advisors lp | 4,975,826 | $23.4M |
| elmind capital, lp | 4,550,000 | $21.4M |
| nextech invest, ltd. | 4,449,932 | $20.9M |
Showing top 10 of 178 institutional holders of CytomX Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 15.5%
- Days to cover
- 7.0
- Shares short
- 29,742,798
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CTMX short interestGovernance
Frequently asked questions
What is the AI investment thesis for CytomX Therapeutics, Inc.?
CytomX Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing conditionally activated PROBODY therapeutics, with its lead candidate CX-2051 in Phase 1/2 trials and a cash position of $17.2M as of 2026-06-30 [sec].
What is CytomX Therapeutics, Inc.'s lead drug candidate?
CytomX Therapeutics, Inc.'s most advanced tracked candidate is CX-2029 (Phase 2) for Solid and hematologic cancers with CD71 (transferrin receptor) expression; Phase 2 expansion included sqNSCLC, HNSCC, E/GEJ cancers, and DLBCL (DLBCL cohort later deprioritized).
Who is the CEO of CytomX Therapeutics, Inc.?
Dr. Sean A. McCarthy DPHIL is the chief executive officer of CytomX Therapeutics, Inc. (CTMX).
Where is CytomX Therapeutics, Inc. headquartered?
CytomX Therapeutics, Inc. (CTMX) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does CytomX Therapeutics, Inc. focus on?
CytomX Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.